Sort   by:  
 Page size 
Vav1, a Rac/Rho guanine nucleotide exchange factor and a critical component of the T cell receptor (TCR) signaling cascade, is rapidly tyrosine phosphorylated in response to T cell activation. Previous studies using Vav1 knockout models have demonstrated its importance in TCR signaling. Although Vav...
ORGANISM(S): Homo sapiens (Human) 
2016-05-31 | PXD002022 | Pride
Chimeric antigen receptor (CAR) T cells have revolutionized the landscape of cancer therapy, demonstrating unprecedented success in treating relapsed or refractory blood cancers. Previous studies of the mechanisms underlying the interactions and responses of CAR T cells and their targets have focuse...
ORGANISM(S): Homo sapiens (Human) 
2025-11-21 | PXD058576 | Pride
We have shown previously that rapamycin, the canonical inhibitor of the mechanistic target of rapamycin (mTOR) complex 1, markedly inhibits the growth of focal lesions in the resistant hepatocyte (Solt-Farber) model of hepatocellular carcinoma (HCC) in the rat. In the present study, we characterized...
ORGANISM(S): Rattus norvegicus (Rat) 
2018-10-26 | PXD005845 | Pride
ζ-associated protein of 70 kDa (Zap70) and interleukin-2-inducible T cell kinase (Itk) propagate the primary and CD28-integrated phosphotyrosine (pY) signalling, respectively, to achieve full T cell activation. Despite their canonical roles in T cell activation, our understanding of how each kinase ...
ORGANISM(S): Homo sapiens (Human) 
2026-04-03 | PXD069485 | Pride
The protein tyrosine phosphatases (PTPs) TCPTP, PTPN22, and SHP1 are critical regulators of the activating phophotyrosine (pY) site on the initiating T cell kinase, LckY394, but the broader implications of these phophatases in T cell receptor (TCR) signalling and T cell biology remain unclear. By co...
ORGANISM(S): Homo sapiens (Human) 
2025-08-01 | PXD058624 | Pride
Adoptive cell therapy, a subset of cancer immunotherapy, is collection of therapeutic approaches which aim to redirect the immune system by reprogramming patient T-cells to target antigenic molecules differentially and specifically expressed in certain cancers. One promising immunotherapy technique ...
ORGANISM(S): Homo sapiens (Human) 
2022-01-28 | PXD028109 | Pride
T cell activation must be properly regulated to ensure normal T cell development and effective immune responses to pathogens and transformed cells, while avoiding autoimmunity. Our knowledge of the mechanisms controlling the fine-tuning of T cell receptor (TCR) signaling and T cell activation is sti...
ORGANISM(S): Homo sapiens (Human) 
2016-05-31 | PXD002023 | Pride
Expanding the sequencing depth of the peptides showing a statistically significant quantitative change arising from a biological stimulation is critical. Here we demonstrate that optimization of LC gradient and analytical column construction can reveal over 30,000 unique peptides and 23,000 phosphop...
ORGANISM(S): Homo sapiens (Human) 
2018-10-26 | PXD005650 | Pride
Although chimeric antigen receptor (CAR) T cell therapy has revolutionised individualised cancer therapies for relapsed/refractory lymphomas, low long-term retention due to basal signalling (antigen-independent activation in the absence of cognate antigen) and off-target toxicity limit the broad app...
ORGANISM(S): Homo sapiens (Human) 
2025-11-21 | PXD065669 | Pride
Sequencing the tyrosine phosphoproteome using MS-based proteomics is challenging due to the low abundance of tyrosine phosphorylation in cells, a challenge compounded in scarce samples like primary cells or clinical samples. The broad-spectrum optimization of selective triggering (BOOST) method was ...
ORGANISM(S): Mus musculus (Mouse) 
2025-12-08 | PXD053863 | Pride
Sort   by:  
 Page size